查看“CAR-NKT”的源代码

<div style="padding: 0 2%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff;">

<div style="margin-bottom: 25px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 20px;">
    <p style="font-size: 1.15em; margin: 10px 0; color: #0f172a; font-weight: 500;">
        <strong>CAR-NKT 细胞疗法</strong>（Chimeric Antigen Receptor Natural Killer T Cell Therapy）系一种利用基因工程技术，在自然杀伤 T 细胞（NKT 细胞）表面表达嵌合抗原受体（[[CAR]]）的先进[[过继性细胞免疫治疗]]范式。该疗法通过 CAR 结构实现对肿瘤抗原的非 MHC 限制性识别，并结合 NKT 细胞识别 **[[CD1d]]** 分子的内源性机制，在杀伤实体瘤及重塑[[肿瘤微环境]]方面展现出独特的双重轴心效应。
    </p>
</div>

<div class="medical-infobox mw-collapsible mw-collapsed" style="float: right; width: 330px; margin: 0 0 25px 25px; border: 1.5px solid #94a3b8; border-radius: 12px; background-color: #ffffff; box-shadow: 0 12px 30px rgba(0,0,0,0.1); overflow: hidden;">
    
    <div style="padding: 18px 15px; color: #ffffff; background: linear-gradient(135deg, #0f172a 0%, #1e40af 100%); text-align: center; cursor: pointer;">
        <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.5px;">CAR-NKT · 核心图谱</div>
        <div style="font-size: 0.75em; opacity: 0.9; margin-top: 5px; white-space: nowrap;">Engineering NKT Axis (点击展开/折叠)</div>
    </div>
    
    <div class="mw-collapsible-content">
        <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
            <div style="display: inline-block; background: #ffffff; border: 1px solid #cbd5e1; border-radius: 8px; padding: 25px; box-shadow: 0 4px 6px rgba(0,0,0,0.05);">
                [[文件:CAR_NKT_Structural_Diagram.png|200px|CAR-NKT结构]]
            </div>
            <div style="font-size: 0.85em; color: #475569; margin-top: 15px; font-weight: 600;">CAR 导向与 CD1d 识别之协同視阈</div>
        </div>

        <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.9em;">
            <tr>
                <th style="text-align: left; padding: 12px 18px; border-bottom: 1px solid #f1f5f9; color: #475569; font-weight: 600; width: 40%; background-color: #f8fafc;">识别限制</th>
                <td style="padding: 12px 18px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">CD1d / CAR-Ag</td>
            </tr>
            <tr>
                <th style="text-align: left; padding: 12px 18px; border-bottom: 1px solid #f1f5f9; color: #475569; font-weight: 600; background-color: #f8fafc;">GVHD 风险</th>
                <td style="padding: 12px 18px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">极低 (支持通用型)</td>
            </tr>
            <tr>
                <th style="text-align: left; padding: 12px 18px; color: #475569; font-weight: 600; background-color: #f8fafc;">核心靶标</th>
                <td style="padding: 12px 18px; color: #1e40af; font-weight: bold;">GD2 / GPC3 / BCMA</td>
            </tr>
        </table>
    </div>
</div>

<h2 style="background: linear-gradient(to right, #0f172a, #3b82f6); color: #ffffff; padding: 10px 18px; border-radius: 4px; font-size: 1.25em; margin-top: 35px; border-left: 6px solid #1e3a8a;">技术特征与药理优势</h2>
<p style="margin: 15px 0;">
    与传统 [[CAR-T]] 相比，CAR-NKT 细胞通过其内源性不变型 TCR 识别非多态性 CD1d 提呈的[[糖脂]]（如 $\alpha$-GalCer），具备以下差异化优势：
</p>
<ul style="padding-left: 20px; color: #334155;">
    <li style="margin-bottom: 12px;"><strong>通用型开发潜力：</strong> 由于 NKT 不识别异体 MHC，其产生移植物抗宿主病（[[GVHD]]）的风险极低，支持“现货型”产品的规模化制备。</li>
    <li style="margin-bottom: 12px;"><strong>TME 靶向与调节：</strong> CAR-NKT 能特异性杀伤肿瘤内表达 CD1d 的抑制性髓系细胞（[[MDSCs]]），从而精准爆破实体瘤的免疫屏蔽层。</li>
</ul>

<h2 style="background: linear-gradient(to right, #0f172a, #3b82f6); color: #ffffff; padding: 10px 18px; border-radius: 4px; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #1e3a8a;">效能横向对照</h2>
<div style="overflow-x: auto; margin: 30px 0;">
    <table style="width: 85%; max-width: 600px; border-collapse: collapse; border: 1px solid #cbd5e1; font-size: 0.95em; text-align: left;">
        <tr style="background-color: #f1f5f9; border-bottom: 2.5px solid #0f172a;">
            <th style="padding: 12px; border: 1px solid #cbd5e1;">维度</th>
            <th style="padding: 12px; border: 1px solid #cbd5e1;">CAR-T</th>
            <th style="padding: 12px; border: 1px solid #cbd5e1;">CAR-NKT</th>
        </tr>
        <tr>
            <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: bold;">异体回输</td>
            <td style="padding: 10px; border: 1px solid #cbd5e1;">高风险</td>
            <td style="padding: 10px; border: 1px solid #cbd5e1; color: #16a34a; font-weight: bold;">极低风险</td>
        </tr>
        <tr>
            <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: bold;">实体瘤浸润</td>
            <td style="padding: 10px; border: 1px solid #cbd5e1;">受限</td>
            <td style="padding: 10px; border: 1px solid #cbd5e1; color: #16a34a; font-weight: bold;">强 (组织驻留)</td>
        </tr>
    </table>
</div>

<h2 style="background: linear-gradient(to right, #0f172a, #3b82f6); color: #ffffff; padding: 10px 18px; border-radius: 4px; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #1e3a8a;">参考文献</h2>
<div style="font-size: 0.9em; line-height: 1.6; color: #1e293b; margin-top: 15px; background-color: #f8fafc; padding: 20px; border-radius: 8px; border-top: 3px solid #0f172a;">
    
    <p style="margin: 10px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
        [1] <strong>Heczey A, et al. (2020).</strong> <em>Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma.</em> <strong>Nature Medicine</strong>. <br>
        <span style="color: #1e40af; font-weight: 500;">[学术点评]：该研究系 CAR-NKT 领域的里程碑成果，首次在临床试验中证实了其在儿童实体瘤中优异的安全性及对肿瘤微环境的调控能力。</span>
    </p>

    <p style="margin: 10px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
        [2] <strong>Godfrey D I, et al. (2018).</strong> <em>The biology and functional diversity of NKT cells.</em> <strong>Nature Reviews Immunology</strong>. <br>
        <span style="color: #1e40af; font-weight: 500;">[学术点评]：权威免疫学综述，系统阐述了 iNKT 细胞作为先天与适应性免疫桥梁的分子生物学基础，为工程化修饰提供了底层理论。</span>
    </p>

    <p style="margin: 10px 0;">
        [3] <strong>Xu X, et al. (2022).</strong> <em>CAR-NKT cells: a promising next-generation of cancer immunotherapy.</em> <strong>Journal of Hematology & Oncology</strong>. <br>
        <span style="color: #1e40af; font-weight: 500;">[学术点评]：深入分析了 CAR-NKT 在异体通用型开发中的 CMC 挑战及未来技术趋势，具有极高的转化医学指导价值。</span>
    </p>
</div>

<div style="margin: 45px 0; border: 1.5px solid #0f172a; border-radius: 8px; overflow: hidden; font-size: 0.95em;">
    <div style="background-color: #0f172a; color: #ffffff; text-align: center; font-weight: bold; padding: 12px; letter-spacing: 2px;">关联词条导引</div>
    <div style="padding: 20px; background: #ffffff; line-height: 2.2; text-align: center;">
        [[NKT细胞]] • [[嵌合抗原受体]] • [[CD1d限制性识别]] • [[神经母细胞瘤]] • [[通用型细胞治疗]]
    </div>
</div>

</div>